Classification of Meningioma Using Immunogenic Antigens

  • Nicole LudwigEmail author
Part of the Tumors of the Central Nervous System book series (TCNS, volume 11)


Diagnosis of meningioma is often an incidental finding. Although the majority of meningioma is clinically benign, a relevant subgroup of them is prone to recur and inherit a poor prognosis. Biological markers for this subgroup or for the early detection of meningioma are not known or not generally accepted. A novel method might improve early detection of meningioma. Autoantibodies generated from the patients’ immune system directed against proteins expressed from the meningioma tumours might aid in early detection of meningioma. Because the autoantibody repertoire reflects the expression of the tumour, autoantibodies also might hold the potential to differentiate between the benign meningiomas and the meningiomas with worse prognosis.


Connective Tissue Growth Factor Control Seron Benign Meningioma Reactive Antigen Meningioma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4:1123–1133PubMedCentralPubMedCrossRefGoogle Scholar
  2. Anderson SK, Gallinger S, Roder J, Frey J, Young HA, Ortaldo JR (1993) A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci U S A 90:542–546PubMedCentralPubMedCrossRefGoogle Scholar
  3. Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM (2011) Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 13:R25PubMedCentralPubMedCrossRefGoogle Scholar
  4. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22:383–389PubMedCentralPubMedCrossRefGoogle Scholar
  5. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873PubMedCrossRefGoogle Scholar
  6. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914–1918PubMedCentralPubMedCrossRefGoogle Scholar
  7. Comtesse N, Heckel D, Rácz A, Brass N, Glass B, Meese E (1999) Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. Clin Cancer Res 5:3560–3568PubMedGoogle Scholar
  8. Comtesse N, Niedermayer I, Glass B, Heckel D, Maldener E, Nastainczyk W, Feiden W, Meese E (2002) MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies. Oncogene 21:239–247PubMedCrossRefGoogle Scholar
  9. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E (2005) Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 102:9601–9606PubMedCentralPubMedCrossRefGoogle Scholar
  10. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76:2420–2424PubMedCentralPubMedCrossRefGoogle Scholar
  11. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A 98:629–634PubMedCentralPubMedCrossRefGoogle Scholar
  12. Heckel D, Brass N, Fischer U, Blin N, Steudel I, Türeci O, Fackler O, Zang KD, Meese E (1997) cDNA cloning and chromosomal mapping of a predicted coiled-coil proline-rich protein immunogenic in meningioma patients. Hum Mol Genet 6:2031–2041PubMedCrossRefGoogle Scholar
  13. Heckel D, Comtesse N, Brass N, Blin N, Zang KD, Meese E (1998) Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum Mol Genet 7:1859–1872PubMedCrossRefGoogle Scholar
  14. Hitchcock E, Morris CS (1987) Immunocytochemistry of intracranial meningiomas. J Neurooncol 5:357–368PubMedCrossRefGoogle Scholar
  15. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP (2006) A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics 7:539PubMedCentralPubMedCrossRefGoogle Scholar
  16. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR (2001) Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1:890–898PubMedCrossRefGoogle Scholar
  17. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9:5120–5126PubMedGoogle Scholar
  18. Levy NL, Mahaley MS Jr, Day ED (1972) In vitro demonstration of cell-mediated immunity to human brain tumors. Cancer Res 32:477–482PubMedGoogle Scholar
  19. Ludwig N, Keller A, Comtesse N, Rheinheimer S, Pallasch C, Fischer U, Fassbender K, Steudel WI, Lenhof HP, Meese E (2008) Pattern of serum autoantibodies allows accurate distinction between a tumor and pathologies of the same organ. Clin Cancer Res 15:4767–4774CrossRefGoogle Scholar
  20. Ludwig N, Keller A, Heisel S, Leidinger P, Rheinheimer S, Andres C, Stephan B, Steudel WI, Donauer E, Graf N, Burgeth B, Weickert J, Lenhof HP, Meese E (2011) Novel immunogenic antigens increase classification accuracy in meningioma to 93.84 %. Int J Cancer 128:1493–1501PubMedCrossRefGoogle Scholar
  21. Monz D, Munnia A, Comtesse N, Fischer U, Steudel WI, Feiden W, Glass B, Meese EU (2001) Novel tankyrase-related gene detected with meningioma-specific sera. Clin Cancer Res 7:113–119PubMedGoogle Scholar
  22. Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M (2011) A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4+ and CD8+ T-cell as well as B-cell responses. Cancer Immunol Immunother 60:1333–1346PubMedCrossRefGoogle Scholar
  23. Oliveira AM, Ross JS, Fletcher JA (2005) Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124:S16–S28PubMedGoogle Scholar
  24. Pancholi V (2001) Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58:902–920PubMedCrossRefGoogle Scholar
  25. Pees HW, Seidel B (1976) Cell-mediated immune response of patients with meningiomas defined in vitro by a [3H] proline microcytotoxicity test. Clin Exp Immunol 24:310–316PubMedCentralPubMedGoogle Scholar
  26. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, Walter JC, LaBaer J (2004) Self-assembling protein microarrays. Science 305:86–90PubMedCrossRefGoogle Scholar
  27. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19:990–999PubMedCentralPubMedCrossRefGoogle Scholar
  28. Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C (2003) Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 63:6948–6955PubMedGoogle Scholar
  29. Rom WN, Goldberg JD, Addrizzo-Harris D, Watson HN, Khilkin M, Greenberg AK, Naidich DP, Crawford B, Eylers E, Liu D, Tan EM (2010) Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 10:234PubMedCentralPubMedCrossRefGoogle Scholar
  30. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810–11813PubMedCentralPubMedCrossRefGoogle Scholar
  31. Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770–774PubMedCrossRefGoogle Scholar
  32. Sioud M, Hansen MH (2001) Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 31:716–725PubMedCrossRefGoogle Scholar
  33. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788PubMedGoogle Scholar
  34. Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2:1767–1775PubMedGoogle Scholar
  35. Ulanet DB, Torbenson M, Dang CV, Casciola-Rosen L, Rosen A (2003) Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci U S A 100:12361–12366PubMedCentralPubMedCrossRefGoogle Scholar
  36. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86:702–712CrossRefGoogle Scholar
  37. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353:1224–1235PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Human Genetics, Medical FacultySaarland UniversityHomburgGermany

Personalised recommendations